Mefenan Pregnancy

• Pregnancy of Mefenan in details
• Mefenan breastfeeding
• Mefenan reviews

Pregnancy of Mefenan in details

Mefenan crosses the placenta (Mackenzie 1985). Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for Mefenan specifically states use should be avoided starting at 30 weeks' gestation.

The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bloor 2013; Bermas 2014).

Mefenan breastfeeding

Due to lack of published clinical experience in nursing mothers and the potential for toxicity, other agents may be preferred.

Use is not recommended. Excreted into human milk: Yes (in trace amounts) Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

1. Cerner Multum, Inc. "Australian Product Information." O 0
2. MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."
3. "Product Information. Ponstel (Mefenan)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
2. Cerner Multum, Inc. "Australian Product Information." O 0
3. "Product Information. Ponstel (Mefenan)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
5. MHRA. Medicines and Health Regulatory Agency "MHRA Drug Safety Update. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate."

References

1. DailyMed. "MEFENAMIC ACID: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Mefenamic Acid (By mouth): This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Mefenamic acid: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 5 here

Information checked by Dr. Sachin Kumar, MD Pharmacology